Login

Financial Snapshot

Revenue
TTM
$14.14B
Gross Margin
TTM
28.84%
Net Income
TTM
$941.5M
Current Assets
2026 Q1
Current Liabilities
2026 Q1
Current Ratio
2026 Q1
172.62%
Total Assets
2026 Q1
Total Liabilities
2026 Q1
Book Value
2026 Q1
$8.746B
Cash
2026 Q1
P/E
TTM
22.44
Free Cash Flow
TTM
$1.384B

Stock Price

Loading...
Market Cap: $21.131 Billion

About Labcorp Holdings Inc

Labcorp Holdings Inc (NYSE: LH) is a clinical laboratory services company that provides diagnostic testing, drug development support, and biopharma laboratory services. The filing excerpts reference two primary business areas: clinical laboratory testing for patients and healthcare providers, and Biopharma Laboratory Services (BLS) supporting pharmaceutical and biotechnology clients. Labcorp operates within a heavily regulated environment governed by CLIA, HIPAA, HITECH, and the Affordable Care Act, among other federal and state frameworks. The company serves managed care organizations (MCOs), accountable care organizations (ACOs), independent physician associations (IPAs), and government payers. The filing also references Clinical Development and Commercialization Services (CDCS) and Companion Diagnostics (CDx) as service categories. The 10-K was filed on 2026-02-24 under accession number 000092014826000111. Specific revenue figures, segment breakdowns, headquarters details, founding year, and CEO tenure are not extractable from the provided filing excerpts and are therefore omitted.

Revenue model
The filing excerpts reference transactional fee-for-service revenue from clinical laboratory testing billed to managed care organizations, government payers, and patients, as well as contract-based revenue from biopharma clients for laboratory and clinical development services. Specific revenue figures and segment percentages are not supported by the provided excerpts.
Products and services
Services referenced in the filing include clinical laboratory testing (laboratory-developed tests, or LDTs), Biopharma Laboratory Services (BLS), Clinical Development and Commercialization Services (CDCS), Companion Diagnostics (CDx), and Clinical Decision Support (CDS). Specific product names or brand details are not extractable from the provided excerpts.
Customers and end markets
Customer types referenced in the filing include managed care organizations (MCOs), accountable care organizations (ACOs), independent physician associations (IPAs), pharmaceutical and biotechnology companies, and government health programs. End markets span clinical diagnostics and drug development support.
Value-chain role
Labcorp operates as a testing and laboratory services provider sitting between specimen collection and clinical or biopharma decision-making, processing diagnostic tests and supporting drug development workflows for healthcare and pharmaceutical clients.
Geographic exposure
The filing references U.S. regulatory frameworks as primary, with mention of Canadian Dollar (CAD) and U.K. Medicines and Healthcare Products Regulatory Commission (MHRA), indicating some international operations. Specific revenue by geography is not supported by the provided excerpts.

Source: SEC 10-K, filed 2026-02-24

Industry: Services-Medical Laboratories Peers: agilon health inc Chemed Corp Cigna Group Quest Diagnostics Inc CVS Health Corp DaVita Inc Oak Street Health, Inc. R1 RCM Inc. /DE Signify Health, Inc.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support